Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorUniversity of Wisconsin, Madison
About this trial
This study aims to investigate whether a novel artificial intelligence based screening strategy (AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education or AI-BRIDGE), which allows primary care providers to screen patients for vision-threatening diabetic eye disease in the primary care clinic, improves screening and follow-up care rates across race/ethnicity groups and reduces racial/ethnic disparities in screening.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed with type 1 or 2 diabetes
No known diabetic eye disease
Medicaid as their primary insurance
Not had an eye exam in the prior year
Disqualifiers
None
Trial design
Design model
Sequential
Treatments tested in this trial
AI
Other interventionAI-based eye screening program
Treatment groups
4,000 Participants
are divided into 2 treatment groupsGroup A: Usual Care ScreeningNo intervention 0 interventions
Group B: AI-BRIDGEExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Proportion of Participants Who Follow Up With Recommended Eye Care
Proportion of patients, by race and ethnicity, who follow-up with recommended eye care in the AI-BRIDGE and usual-care arms within 6 months of the recommendation.
Time frame
up to 6 monthsSecondary outcomes
1
Difference in Proportion of White vs Hispanic and White vs Black Participants Who Get Eye Screening
Difference in proportion of White vs Hispanic and White vs Black patients who get AI-BRIDGE and usual-care screening within 6 months of the recommendation.
Time frame
up to 6 months2
Proportion of Participants By Race and Ethnicity Who Get Eye Screening
Proportion of Participants by race and ethnicity who get eye screening in the AI-BRIDGE and usual-care arms within 6 months of the recommendation.
Time frame
up to 6 monthsOther outcomes
1
Level of Diabetic Retinopathy
The rate of diabetic retinopathy, count of unique diabetic retinopathy diagnosis divided by count of all enrolled patients, stratified by intervention, intervention and race and ethnicity groups, and intervention, race and ethnicity group, and clinic.
Time frame
up to 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Wisconsin, Madison
Lead sponsor
National Eye Institute (NEI)
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: